Intra-abdominal Sepsis

  • Marc E. Brozovich
  • Peter W. Marcello


Postoperative infection has surpassed hemorrhage as the leading cause of mortality among surgical patients. Despite advances in diagnostic modalities, antibiotic therapy, and critical care medicine, mortality remains high. Intra-abdominal infection is defined as an inflammatory response of the peritoneum to microorganisms and their toxins, which results in purulent exudate in the abdominal cavity.1 The transition from intra-abdominal infection to intra-abdominal sepsis occurs when the domain of the local inflammatory process breaches the abdominal cavity and the patient develops the systemic, physiologic, and immunologic manifestations of inflammation. This chapter reviews the systemic response to inflammation, the causes of intra-abdominal sepsis, its diagnosis, and management.


Surgical Patient Systemic Inflammatory Response Syndrome Drotrecogin Alfa Acalculous Cholecystitis Percutaneous Cholecystostomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wittman DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg. 1996;224:10–18.CrossRefGoogle Scholar
  2. 2.
    Fry DE. Sepsis syndrome. Am Surg. 2000;66:126–132.PubMedGoogle Scholar
  3. 3.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874.CrossRefGoogle Scholar
  4. 4.
    Velmahos GC, Kamel E, Berne TV, et al. Abdominal computed tomography for the diagnosis of intra-abdominal sepsis in critically injured patients: fishing in murky waters. Arch Surg. 1999;134:831–836.PubMedCrossRefGoogle Scholar
  5. 5.
    Weinstein WM, Onderdonk AH, Bartlett JG, et al. Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun. 1974;10:1250–1255.PubMedGoogle Scholar
  6. 6.
    Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection: a Surgical Infection Society policy statement. Arch Surg. 1992;127:83–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt). 2002;3:161–173.CrossRefGoogle Scholar
  8. 8.
    Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt). 2002;3:175–233.PubMedCrossRefGoogle Scholar
  9. 9.
    Wilmore DW, Smith RJ, O’Dwyer ST, et al. The gut: a central organ after surgical stress. Surgery. 1988;104:917–923.PubMedGoogle Scholar
  10. 10.
    Gerzof SG, Robbins AH, et al. Percutaneous catheter drainage of abdominal abscesses: a five year experience. N Engl J Med. 1981;305:653–657.PubMedCrossRefGoogle Scholar
  11. 11.
    Bohnen J, Mustard R, Oxholm S, et al. Apache II score and abdominal sepsis: a prospective study. Arch Surg. 1988;123:225–229.PubMedCrossRefGoogle Scholar
  12. 12.
    Wickel DJ, Cheadle WG, Mercer-Jones MA, et al. Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann Surg. 1997;225:744–756.PubMedCrossRefGoogle Scholar
  13. 13.
    Cornwell EE 3rd, Rodriguez A, Mirvis SE, et al. Acute acalculous cholecystitis in critically injured patients. Ann Surg. 1989;210:52–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Savino JA, Scalea TM, Del Guercio LRM. Factors encouraging laparotomy in acalculous cholecystitis. Crit Care Med. 1985;13:377–380.PubMedCrossRefGoogle Scholar
  15. 15.
    Long TM, Heimbach DM, Carrico CJ. Acalculous cholecystitis in critically ill patients. Am J Surg. 1978;136:31–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Greif WM, Forse A. Hemodynamic effect of the laparoscopic pneumoperitoneum during sepsis in a porcine endotoxic shock model. Ann Surg. 1998;227:474–480.PubMedCrossRefGoogle Scholar
  17. 17.
    Greif WM, Forse A. Interventions to improve cardiopulmonary hemodynamics during laparoscopy in a porcine sepsis model. J Am Coll Surg. 1999;189:450–458.CrossRefGoogle Scholar
  18. 18.
    Jacobi CA, Ordemann J, Zieren HU, et al. Increase systemic inflammation after laparotomy vs laparoscopy in an animal model of peritonitis. Arch Surg. 1998;133:258–262.PubMedCrossRefGoogle Scholar
  19. 19.
    Balague C, Targarona EM, Pujol M, et al. Peritoneal response to a septic challenge: comparison between open laparotomy, pneumoperitoneum laparoscopy, and wall lift laparoscopy. Surg Endosc. 1999;13:792–796.PubMedCrossRefGoogle Scholar
  20. 20.
    Brandt CP, Priebe PP, Eckhauser ML. Diagnostic laparoscopy in the intensive care patient: avoiding the nontherapeutic laparotomy. Surg Endosc. 1993;7:168–172.PubMedCrossRefGoogle Scholar
  21. 21.
    Orlando R 3rd, Corwell KL. Laparoscopy in the critically ill. Surg Endosc. 1997;11:1072–1074.PubMedCrossRefGoogle Scholar
  22. 22.
    McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med. 1994;121:1–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Cohen J, Carlet J. Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor – in patients with sepsis. International Sepsis Investigation Group. Crit Care Med. 1996;24:1431–1440.PubMedCrossRefGoogle Scholar
  24. 24.
    Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirming interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double blinded, placebo-controlled, multicenter trial. Interleukin-1 Receptor Antagonist Sepsis Investigation Group. Crit Care Med. 1997;25:1115–1124.PubMedCrossRefGoogle Scholar
  25. 25.
    Fein Am, Bernanrd GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndromes and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): results of a randomized, double blinded, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 1997;277:482–487.PubMedCrossRefGoogle Scholar
  26. 26.
    Strand OA, Leone AM, Giercksky KE, et al. NG-monomethyl-L-arginine improves survival in a pig model of abdominal sepsis. Crit Care Med. 1998;26:1490–1499.PubMedCrossRefGoogle Scholar
  27. 27.
    Doig GS, Martin CM, Sibbald WJ. Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. Crit Care Med. 1997;25:1956–1961.PubMedCrossRefGoogle Scholar
  28. 28.
    Davis KA, Fabian TC, Ragsdale N, et al. Granulocyte colony-stimulating factor and neutrophil-related changes in local host defense during recovery from shock and intra-abdominal sepsis. Surgery. 1999;126:305–313.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang P, Bagby GJ, Stolz DA, et al. Enhancement of peritoneal leukocyte function by granulocyte stimulating factor in rats with abdominal sepsis. Crit Care Med. 1998;26:315–321.PubMedCrossRefGoogle Scholar
  30. 30.
    Tzianabos AO, Gibson FC 3rd, Cisneros RL, et al. Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. J Infect Dis. 1998;178:200–206.PubMedCrossRefGoogle Scholar
  31. 31.
    Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.PubMedCrossRefGoogle Scholar
  32. 32.
    Barie PS, Williams MD, McCpllam JS, et al. Benefit/ risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg. 2004;188:212–220.PubMedCrossRefGoogle Scholar
  33. 33.
    Payen D, Sablotzki A, Barie PS, et al. International integrated data base for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery. 2007;141:548–561.PubMedCrossRefGoogle Scholar
  34. 34.
    Ely EW, Laterre PF, Angus DC, et al. drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003;31:12–19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Marc E. Brozovich
    • 1
  • Peter W. Marcello
    • 2
  1. 1.Department of Surgical OncologyUniversity of Pittsburgh Medical CenterWexfordUSA
  2. 2.Department of Colon and Rectal SurgeryLahey Clinic Medical CenterBurlingtonUSA

Personalised recommendations